Myriad Genetics says study validates polygenic risk score for breast cancer
Myriad Genetics announced that results of a new validation study of the company's polygenic risk score for breast cancer were presented at the 2019 San Antonio Breast Cancer Symposium. "The key finding is that the PRS significantly improves the precision and accuracy of breast cancer risk estimates for women of European ancestry who have pathogenic variants in high- and moderate-penetrance breast cancer genes," the company said in a statement. "Our goal is to help women understand their risk of breast cancer so that they can take steps to live longer, healthier lives. Women who have a family history of breast cancer should consider hereditary cancer testing with the myRisk Hereditary Cancer test," said Jerry Lanchbury, Ph.D., chief scientific officer of Myriad Genetics. "In this landmark study, we demonstrated that for women who test positive for a mutation in one of the five most common breast cancer genes, there are additional genetic factors called single nucleotide polymorphisms that can further influence their lifetime risk of breast cancer."